Here are four things to know about the deal.
1. Capsugel, based in Morristown, N.J., manufactures empty drug capsules, along with several other drug delivery systems.
3. Lonza’s shares fell by more than 7 percent to 157 Swiss francs ($154) per share upon news of the acquisition, which cost the Swiss company more than 60 percent of its market value.
4. The deal is expected to close in the second quarter of 2017.
More articles on supply chain:
FDA approves Pfitzer’s eczema treatment
5 latest FDA approvals
7 supply chain lessons from auto and retail industries
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
